hot news

The research by Professor Mou, Jianjun's team from the Shaanxi International Medical Exchange Promotion Association was showcased on the ESC stage, revealing that metformin can significantly reduce the risk of atrial fibrillation and stroke in patients with type 2 diabetes.

Recently, the 2024 European Society of Cardiology (ESC) Congress was grandly held in London, UK, focusing on the core theme of "Personalized Cardiovascular Care." Experts and scholars from around the world in the fields of cardiovascular basic science, clinical practice, and prevention gathered to explore a new era in personalized treatment for cardiovascular diseases. During the conference, Dr. Guo, Tongshuai from Professor Mu Jianjun's team at the First Affiliated Hospital of Xi'an Jiaotong University presented the results of their study titled "The effect of metformin use on the risk of atrial fibrillation in patients with type 2 diabetes: data from the UK Biobank."

Objective

This study aims to investigate how metformin protects type 2 diabetes (T2DM) patients, who are also undergoing treatment with other glucose-lowering drugs, from the risks of atrial fibrillation (AF) and stroke.

Methods

The study included 10,011 T2DM patients from the UK Biobank, with follow-up on newly diagnosed cases of atrial fibrillation and stroke (up to 2023). Logistic regression analysis and competing risk models were used to assess the relationship between metformin use and the incidence of atrial fibrillation or stroke.

Conclusion

The results indicate that metformin treatment significantly reduces the risk of atrial fibrillation and stroke compared to other glucose-lowering drugs, particularly reducing the risk of atrial fibrillation in non-insulin users and the risk of stroke in insulin users.